Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3-4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.
第一作者机构：[1]Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Dept Med Oncol, Canc Ctr,State Key Lab Oncol South China,Guangdong, Guangzhou 510060, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Huang Huageng,Zhang Wei,Deng Xinyi,et al.Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting[J].EXPERIMENTAL HEMATOLOGY & ONCOLOGY.2024,13(1):doi:10.1186/s40164-024-00510-w.
APA：
Huang, Huageng,Zhang, Wei,Deng, Xinyi,Huang, He,Wang, Zhao...&Lin, Tongyu.(2024).Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting.EXPERIMENTAL HEMATOLOGY & ONCOLOGY,13,(1)
MLA：
Huang, Huageng,et al."Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting".EXPERIMENTAL HEMATOLOGY & ONCOLOGY 13..1(2024)
